ARTICLE | Company News
Abpro, AstraZeneca deal
December 2, 2016 9:49 PM UTC
The MedImmune LLC unit of AstraZeneca and Abpro partnered to develop MedImmune's preclinical bispecific antibody that targets angiopoietin 2 (ANG2; ANGPT2) and VEGF for multiple undisclosed indicatio...
BCIQ Target Profiles